Abstract
The role of palmitoylethanolamide (PEA) in the regulation of complex systems involved in the inflammatory response, pruritus, neurogenic and neuropathic pain is well understood. Growing evidence indicates that this Nacylethanolamine also exerts neuroprotective effects within the central nervous system (CNS), i.e. in spinal cord and traumatic brain injuries and in age-related pathological processes. PEA is abundant in the CNS, and is produced by glial cells. Several studies show that administering PEA during the first few hours after injury significantly limits CNS damage, reduces loss of neuronal tissue and improves functional recovery. PEA appears to exert its protective effect by decreasing the development of cerebral edema, down-regulating the inflammatory cascade, and limiting cellular necrosis and apoptosis. All these are plausible mechanisms of neuroprotection. This review provides an overview of current knowledge of PEA effect on glial functions in the brain and how targeting glial-specific pathways might ultimately impact the development of therapies for clinical management of neurodegenerative disorders. The diverse signaling mechanisms are also summarized.
Keywords: Glial cells, N-acylethanolamine, neuroprotection, spinal cord
CNS & Neurological Disorders - Drug Targets
Title:Palmitoylethanolamide in Homeostatic and Traumatic Central Nervous System Injuries
Volume: 12 Issue: 1
Author(s): Emanuela Esposito and Salvatore Cuzzocrea
Affiliation:
Keywords: Glial cells, N-acylethanolamine, neuroprotection, spinal cord
Abstract: The role of palmitoylethanolamide (PEA) in the regulation of complex systems involved in the inflammatory response, pruritus, neurogenic and neuropathic pain is well understood. Growing evidence indicates that this Nacylethanolamine also exerts neuroprotective effects within the central nervous system (CNS), i.e. in spinal cord and traumatic brain injuries and in age-related pathological processes. PEA is abundant in the CNS, and is produced by glial cells. Several studies show that administering PEA during the first few hours after injury significantly limits CNS damage, reduces loss of neuronal tissue and improves functional recovery. PEA appears to exert its protective effect by decreasing the development of cerebral edema, down-regulating the inflammatory cascade, and limiting cellular necrosis and apoptosis. All these are plausible mechanisms of neuroprotection. This review provides an overview of current knowledge of PEA effect on glial functions in the brain and how targeting glial-specific pathways might ultimately impact the development of therapies for clinical management of neurodegenerative disorders. The diverse signaling mechanisms are also summarized.
Export Options
About this article
Cite this article as:
Esposito Emanuela and Cuzzocrea Salvatore, Palmitoylethanolamide in Homeostatic and Traumatic Central Nervous System Injuries, CNS & Neurological Disorders - Drug Targets 2013; 12 (1) . https://dx.doi.org/10.2174/1871527311312010010
DOI https://dx.doi.org/10.2174/1871527311312010010 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Big Data Mining for CNS Diseases Analysis and Treatment: Focusing on Drug Target Discovery
Central nervous system (CNS) diseases, including neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis, represent a major global health challenge. Despite significant research efforts, the complexity and multifactorial nature of these diseases hinder the development of effective treatments. The rise of big data analytics and high-throughput technologies ...read more
Heart and Brain Axis Targets in CNS Neurological Disorders
Recently, there has been a surge of interest in delving deeper into the complex interplay between the heart and brain. This fascination stems from a growing recognition of the profound influence each organ holds over the other, particularly in the realm of central nervous system and neurological disorders. The purpose ...read more
Innovative Therapeutics in Demyelinating CNS- Disorders: Immune Modulation, Antibody Therapy, Kinase Inhibition and Remyeliation Strategies
Demyelinating disorders, particularly multiple sclerosis represent chronic disease characterized by inflammation, demyelination, and neurodegeneration within the central nervous system. This thematic issue will present a comprehensive overview of novel therapeutic advances targeting these processes. In addition to dissecting the roles of innate versus adaptive immunity, antibody therapies, and tyrosine kinase ...read more
Lifestyle Interventions to Prevent and Treat Cognitive Impairment and Dementia
More than 55 million people live with dementia worldwide. By 2050, the population affected by dementia will exceed 139 million individuals. Mild cognitive impairment (MCI) is a pre-dementia stage, also known as prodromal dementia, affecting older adults. MCI emerges years before the manifestation of dementia but can be avoidable and ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Combined Therapies for Lysosomal Storage Diseases
Current Molecular Medicine Alzheimers Disease Burdens African-Americans: A Review of Epidemiological Risk Factors and Implications for Prevention and Treatment
Current Psychiatry Reviews Peroxisome Proliferator-Activated Receptor-γ and Its Ligands in the Treatment of Tumors in the Nervous System
Current Stem Cell Research & Therapy An Inventory of Short Term and Long Term Changes in Gene Expression Under Interferon β Treatment of Relapsing Remitting MS Patients
Current Pharmaceutical Design Contemporary Treatment of Amyloid Heart Disease
Current Pharmaceutical Design α7 Nicotinic Acetylcholine Receptor Subunit in Angiogenesis and Epithelial to Mesenchymal Transition
Current Drug Targets Selected Pharmaceutical Excipient Prevent Isoniazid and Rifampicin Induced Hepatotoxicity
Current Drug Metabolism Lipoproteins, Stroke and Statins
Current Vascular Pharmacology Pharmacology and Therapeutic Applications of A1 Adenosine Receptor Ligands
Current Topics in Medicinal Chemistry Growth Factor Changes in Cerebrospinal Fluid of Children with Mental Retardation before and after Neural Precursor Cell Transplantation
CNS & Neurological Disorders - Drug Targets Effects of Proteoglycans on Oxidative/Nitrative Stress
Current Organic Chemistry Cannabinoids and Brain Damage: A Systematic Review on a Frequently Overlooked Issue
Current Pharmaceutical Biotechnology 5HT1F- and 5HT7-Receptor Agonists for the Treatment of Migraines
CNS & Neurological Disorders - Drug Targets Natural-based Hydrogels: A Journey from Simple to Smart Networks for Medical Examination
Current Medicinal Chemistry Therapeutic Trials in Human Transmissible Spongiform Encephalopathies: Recent Advances and Problems to Address
Infectious Disorders - Drug Targets Endogenous Cardioprotective Agents: Role in Pre and Postconditioning
Current Drug Targets Use of Toll-Like Receptor 3 Agonists Against Respiratory Viral Infections
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Role of Cerium Oxide Nanoparticles and Doxorubicin in Improving Cancer Management: A Mini Review
Current Pharmaceutical Design Pharmacological Manipulation of Brain Glycogenolysis as a Therapeutic Approach to Cerebral Ischemia
Mini-Reviews in Medicinal Chemistry Effect of Nanotechnology Approaches on Anti-retroviral Molecule: Efavirenz
Current Organic Chemistry